OxyDeplete (Oxygen-Depleted Sealed): near-zero-oxygen storage for oxidation-prone peptides

1.  Field of the invention — protecting oxidation-prone peptides

A dried peptide holds its potency far longer when one quiet variable is taken off the table. That variable is oxidation¹, the slow reaction between the molecule and the oxygen sealed in alongside it — and it is one of the most controllable factors in a product's shelf life. Three residues carry most of the exposure — methionine oxidises to methionine sulfoxide², cysteine thiols scramble into disulfides, and tryptophan and histidine open under reactive-oxygen attack⁶. None of this needs heat or light to begin; ground-state molecular oxygen, given months, is enough. The result is a lower potency, a new impurity peak, or an aggregation seed — degradation that was written into the vial the moment it was closed with air still inside.

2.  The residual-headspace problem

Every sealed vial carries a headspace: the void above the product, normally filled with room air at roughly 21 % oxygen. That trapped oxygen is a finite but sufficient reservoir — it does not escape, it reacts. For an oxidation-sensitive sequence, headspace oxygen is a primary determinant of how long the product stays intact in storage. Many conventional lyophilization cycles remove water with great care, then close the cake back up under air — solving one degradation pathway while leaving the oxidative one open. Not every lyophilised product is air-sealed, but wherever accessible gas is left in, OxyDeplete depletes it before the container is completed.

3.  Summary of the method

What "Oxygen-Depleted Sealed" means

OxyDeplete treats gas as the control variable. Rather than accept whatever gas a unit happens to contain, the accessible gas is drawn out before the container is completed — in a dried cake the accessible pore gas, entrapped gas and chamber atmosphere; in a liquid the dissolved gases and entrained microbubbles. OxyDeplete performs the gas removal only: it does not backfill the argon and it does not form the seal. The argon then arrives in two distinct events. First, as the Lyochrysalis™ lyophilisation cycle closes, argon admitted by ArgonLock™ replaces all the vacuum over the dried cakes — a full argon backfill of the porous solid. Later, once the cartridge is capped, the Vana Machine™ draws the Lyoprester® dry (first) chamber back to an absolute vacuum and replaces only a fraction of that vacuum with argon before locking the closure — leaving a vacuum-derived, strongly oxygen-reduced chamber that sits at reduced pressure carrying partial argon, not a headspace ‘backfilled’ at atmospheric pressure. This mirrors, at pharmaceutical precision, the food-and-pharma logic of modified-atmosphere packaging³ and oxygen scavengers⁴: control the gas, and you control the chemistry.

4.  Detailed description — the sequence

Steps [01]–[06] describe the principle only, and the argon is admitted by ArgonLock™ — not by OxyDeplete. The pressures, dwell times, gas selection and closure hardware that make the depletion repeatable are not disclosed.

5.  Characteristics & advantages

The advantage is mechanistic, not cosmetic: OxyDeplete does not slow oxidation with an additive that must itself be justified in the formulation — it depletes the accessible gas so the argon conditioning that follows works against a much lower oxygen load. Molecular oxygen is a major contributor to several oxidative pathways, while RedoxVault™ addresses formulation-specific risks involving peroxides, reactive species, trace metals and other redox-active contaminants.

6.  System integration — Panacea's contribution

Gas depletion is strongest inside a formulation-integrity chain rather than bolted on at the end. OxyDeplete hands off within Panacea's gentle drying and inert-conditioning stack. Product is freeze-dried by Cryolapse™ — freeze-drying the way nature would →; OxyDeplete then depletes the accessible gas; ArgonLock™ — controlled argon conditioning → establishes the argon-conditioned state across its three faces — dissolved argon in the P-EARLs™ diluent, dissolved argon in the Liquiprester™ liquid, and gas-phase argon in the Lyoprester® dry chamber, where argon first replaces all the vacuum as the Lyochrysalis™ cycle closes and is later reduced by the Vana Machine™ to a partial argon fill of a re-drawn vacuum; and the Vana Machine™ conditions the vacuum and locks the closure. Each technology owns one step: OxyDeplete removes the gas, ArgonLock supplies and conditions the argon, Vana controls the vacuum and closure, and the container-closure preserves the condition over shelf life. Where the surviving risk is redox rather than gaseous, RedoxVault™ provides formulation-specific protection. The choreography across these stages is watched by the S3Pulse™ control algorithm →.

A low-temperature finish. Panacea's lyophilisation is not a hot process. Coordinated by Lyochrysalis™, S3Pulse™, DiastolVAC™, TgShift™, Cryolapse™ and LyoLevit™, the cycle finishes at −3 to −5 °C — primary drying (sublimation) ending at −8 to −10 °C and secondary drying (desorption) ending at −3 to −5 °C — with none of the +40 to +60 °C secondary-drying overheat that mainstream lyophilisation consensus requires. Removing that thermal stress preserves the binding affinity and bioavailability of the finished peptide, so OxyDeplete gas depletion goes on to protect a molecule that was never overheated in the first place.

Two further Panacea methods sharpen the depletion at the two moments that matter most — drawing the gas out, and keeping it out. The degas step is shaped by DiastolVAC™ — vacuum with a heartbeat →, whose gentle, pulsed pressure curve coaxes adsorbed gas out of a delicate cake far more evenly than a single hard vacuum, so the depletion reaches deep without stressing the product. And once the unit is sealed, the Vana Machine™ — the seal that stays put → conditions the closure under vacuum and locks it, so no plunger drift or slow in-leak lets an air gap — and its oxygen — creep back over the shelf life. Together they mean the very low oxygen established by OxyDeplete gas depletion and ArgonLock argon conditioning is the same low-oxygen condition the product still sees months later. Within qualified Panacea formulations and container architectures, that integrated process has demonstrated stability extending into years.

Panacea's newest contribution. OxyDeplete is Panacea Bio Chem's latest step in a longer programme of oxygen-exclusion research: taking accessible-gas depletion beyond a single fill-line trick and into a repeatable, integrity-controlled stage of the peptide workflow. What sets it apart — how the depletion is driven and held — is held in-house.

OxyDeplete™ is a proprietary Panacea Bio Chem gas-depletion technology developed and invented by Bogdan Dicoias; its operating parameters are not publicly disclosed. The rough principle is stated above — the exact degassing pressures, dwell times and the argon-conditioning handoff that make OxyDeplete repeatable stay behind the door.

7.  Precedent — borrowed from the food that lasts

Excluding oxygen to buy shelf life is one of the oldest preservation moves there is, and industry proved it at scale long before pharma refined it. A vacuum- or nitrogen-flushed pack of coffee, a nitrogen-topped wine, a sachet of iron powder tucked beside dried food — each is the same idea: take the oxygen out of the container and the contents stop ageing. Modified-atmosphere packaging³ swaps air for inert gas; oxygen scavengers⁴ chemically mop up whatever remains; both are everyday defences against autoxidation⁵, the slow, spontaneous reaction of organic matter with air. OxyDeplete carries that well-worn food-and-pharma logic to the precision a fragile peptide demands: not "less" oxygen, but as close to none as a sealed vial allows.

8.  Application fields

• Oxidation-sensitive peptides & proteins — sequences whose potency hinges on intact methionine, cysteine or tryptophan.
• Methionine-rich sequences — where a single sulfoxide conversion shifts the impurity profile.
• Long-shelf-life stockpiles — strategic or clinical reserves that must hold potency for years, not months.
• Ambient-stable formulations — products intended to travel and store without a cold chain, where oxidation is the dominant ageing path.
• Dual-chamber cartridges — e.g. Lyoprester®, the cartridge that reconstitutes itself →, where the dry chamber benefits directly from an oxygen-depleted seal.

9.  How much oxygen is acceptable? The numbers, and their units

“Residual oxygen” is two different measurements wearing one name, and they are not interchangeable. In a liquid, dissolved oxygen is counted in parts per million (mg/L) — air-saturated water at room temperature holds roughly 8–9 ppm. In a sealed dry unit, headspace oxygen is a gas-phase fraction, counted in percent by volume. Henry’s law connects the two regimes through the gas–liquid equilibrium, but a number from one regime says nothing direct about the other — the confusion is real enough to live inside the patent literature itself, where one packaging document equates “1% residual oxygen” with “~400 ppb” without stating which regime it means¹². A residual-oxygen figure means nothing until its regime travels with it.

Two orientation facts frame every number above. First, water for injection itself carries no pharmacopoeial dissolved-oxygen specification: the USP monograph limits conductivity, total organic carbon, endotoxin, microbial count and pH — and says nothing about dissolved oxygen, so any “WFI oxygen spec” quoted without a source is folklore. Second, oxygen displacement for oxidisable injectables is long-standing written practice, not a novelty: the Chinese Pharmacopoeia (2020, general chapter 0102 on injections) directs that container air be displaced with carbon dioxide or nitrogen and the container sealed immediately for air-sensitive drugs, and the Soviet-school parenteral canon teaches gas-saturation of water for injection to the same end. Where a finished product lands between a few ppm dissolved and a few percent headspace is therefore an engineering decision with published precedent on both sides — and it is the decision OxyDeplete exists to drive downward before ArgonLock™ conditioning and the Vana Machine™ closure hold it there.

10.  Oxidation prevention without antioxidants — the precedent

The classic defence for an oxygen-sensitive drug was to add an antioxidant — sodium metabisulfite being the workhorse — and let it be consumed in the molecule’s place. That route has real costs: sulfite reactions in some patients pushed the field toward products that could do without, and every antioxidant added is one more excipient to justify, one that is spent as it reacts. The alternative — remove the oxygen instead of sacrificing an additive to it — is not a theory. It is written into product and patent history:

• Epinephrine. One stability programme purges the water for injection with nitrogen until dissolved oxygen falls below 1 ppm before the drug is compounded — deoxygenation doing the work the sulfite tradition used to carry alone¹⁰.
• L-cysteine injection. A patent family builds the product expressly on dissolved oxygen below about 2 ppm, so that a sulfite-warning-era injectable needs no added antioxidant at all¹¹.
• Packaging-side removal. Oxygen-scavenging packaging systems were developed around a recognised list of oxygen-sensitive drugs — morphine, dopamine, epinephrine among them¹² — and “pharmaceutical composition not containing antioxidant” exists as a stated patent objective in its own right¹³.

OxyDeplete stands in that lineage. An antioxidant sits inside the formulation and is consumed as it reacts; OxyDeplete withholds the oxidiser from the product and its container instead — the two levers can be combined, and the cases oxygen removal cannot reach (peroxides, trace metals, reactive species carried by excipients) belong to RedoxVault™ by design.

Frequently asked

Trending in the field

OxyDeplete in liquids

OxyDeplete’s gas-depletion principle covers every liquid Panacea processes — not only the cartridge fill liquids but the peptide solution itself, before it is lyophilised. OxyDeplete™ and ArgonLock™ are applied to all three: the peptide solution ahead of freeze-drying, the P-EARLs™ diluent, and the Liquiprester™ precision liquid cartridge. In each, the liquid is degassed to remove dissolved atmospheric gases, entrained microbubbles and accessible oxygen before argon conditioning — so the active enters the dry cake, and each cartridge is filled, from an already oxygen-depleted, argon-conditioned starting point. OxyDeplete removes the gas; ArgonLock™ then establishes the argon-conditioned state by dissolving controlled argon into the liquid, and ElimiVoid™ geometrically completes the front void — together giving a cartridge with no visible air bubble, within a near-airless, oxygen-depleted, argon-conditioned environment. Those cartridges are filled on the PleniDose™ Gantry, conditioned into the Cryoviscous™ state, protected by RedoxVault™, and dose-mapped per increment by IncreSure™.

References & further reading

1. Protein oxidation — oxidative modification of amino-acid residues. Wikipedia.
2. Methionine and its oxidation to methionine sulfoxide. Wikipedia.
3. Modified-atmosphere packaging. Wikipedia.
4. Oxygen scavenger. Wikipedia.
5. Autoxidation — spontaneous oxidation in air. Wikipedia.
6. Reactive oxygen species and residue damage. Wikipedia.
7. Butler IB, et al. — Removal of dissolved oxygen from water: a comparison of four common techniques. Talanta, 1994. PubMed.
8. Stabilized peptide composition — headspace oxygen vs related substances in lyophilized peptide vials. US 12,491,229 (patent). patent.
9. IL-17 antibody formulations — 5% vs 20% headspace oxygen related-substances data. US 12,296,008 (patent family). patent.
10. Stable epinephrine compositions — water for injection nitrogen-purged below 1 ppm dissolved oxygen. US 11,234,925 (patent). patent.
11. L-cysteine injection — dissolved oxygen below about 2 ppm without added antioxidant. US 10,653,719 (patent family). patent.
12. Packaging system for oxygen-sensitive drugs. EP 2968729 (patent). patent.
13. Pharmaceutical composition not containing antioxidant. US 10,300,063 (patent). patent.
14. Oxygen-scavenging package. US 2006/0076536 (patent application). patent.